Dr. Adriana Lesca
Nuclear Medicine Department "Città dell Salute e della Scienza", Torino
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
15Years (2012-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 September 2012 in International Journal of Radiation Oncology, Biology, Physics
Journal Article
Massimiliano MistrangeloEPEttore Pelosi
Ettore Pelosi
MBMarilena Bellò
Marilena Bellò
URUmberto Ricardi
Umberto RicardiEMEnrica Milanesi
Enrica Milanesi
MMMario Morino
Mario Morino +9
Journal Article
FAFrancesca Arcadipane
Francesca ArcadipanePSPatrick Silvetti
Patrick SilvettiFOFrancesco Olivero
Francesco OliveroAGAlessio Gastino
Alessio GastinoVLViola De Luca
Viola De Luca
Pierfrancesco Franco +7
Purpose: to investigate the role of selective avoidance of hematopoietically active BM within the pelvis, as defined with 18FDG-PET, employing a targeted IMRT approach, to reduce acute hematologic toxicity (HT) profile in anal cancer patients undergoing concurrent chemo-radiation. Methods: a one-armed two-stage Simon’s design was selected to test the hypothesis that BM-sparing approach would improve by 20% the rate of G0–G2 (vs. G3–G4) HT, from 42% of RTOG 0529 historical data to 62% (α = 0.05 and the β = 0.20). At the first stage, among 21 enrolled patients, at least 9 should report G0–G2 acute HT to further proceed with the trial. We employed 18FDG-PET to identify active BM within the pelvis. Acute HT was assessed via weekly blood counts and scored as per the Common Toxicity Criteria for Adverse Effects version 4.0. Results: from December 2017 to October 2019, 21 patients were enrolled. Maximum observed acute HT comprised 9% rate of ≥G3 leukopenia and 5% rate of ≥G3 neutropenia and anemia. Overall, only 4 out of 21 treated patients (19%) experienced ≥G3 acute HT. Conversely, 17 patients (81%) experienced G0–G2 events, way above the threshold set by the trial design. Conclusion: 18FDG-PET-guided BM-sparing IMRT was able to reduce acute HT in anal cancer patients treated with concomitant chemo-radiation. These results prompted us to conclude the second part of this prospective phase II trial.
8 June 2016 in Medical Oncology
Journal Article
Pierfrancesco FrancoFAFrancesca Arcadipane
Francesca Arcadipane
RRRiccardo Ragona
Riccardo Ragona
Adriana LescaEGElena Gallio
Elena GallioURUmberto Ricardi
Umberto Ricardi
+7
Journal Article
FAFrancesca Arcadipane
Francesca ArcadipanePSPatrick Silvetti
Patrick SilvettiFOFrancesco Olivero
Francesco OliveroAGAlessio Gastino
Alessio GastinoRCRoberta Carlevato
Roberta CarlevatoPierfrancesco Franco +11
We investigated the role of the selective avoidance of haematopoietically active pelvic bone marrow (BM), with a targeted intensity-modulated radiotherapy (IMRT) approach, to reduce acute hematologic toxicity (HT) in anal cancer patients undergoing concurrent chemo-radiation. We designed a one-armed two-stage Simon’s design study to test the hypothesis that BM-sparing IMRT would improve by 20% the rate of G0–G2 (vs. G3–G4) HT, from 42% of RTOG 0529 historical data to 62% (α = 0.05; β = 0.20). A minimum of 21/39 (54%) with G0–G2 toxicity represented the threshold for the fulfilment of the criteria to define this approach as ‘promising’. We employed 18FDG-PET to identify active BM within the pelvis. Acute HT was assessed via weekly blood counts and scored as per the Common Toxicity Criteria for Adverse Effects version 4.0. From December 2017 to October 2020, we enrolled 39 patients. Maximum observed acute HT comprised 20% rate of ≥G3 leukopenia and 11% rate of ≥G3 thrombocytopenia. Overall, 11 out of 39 treated patients (28%) experienced ≥G3 acute HT. Conversely, in 28 patients (72%) G0–G2 HT events were observed, above the threshold set. Hence, 18FDG-PET-guided BM-sparing IMRT was able to reduce acute HT in this clinical setting.
28 May 2018 in Cancer Investigation
Journal Article
Pierfrancesco FrancoFAFrancesca Arcadipane
Francesca Arcadipane
RRRiccardo Ragona
Riccardo Ragona
Adriana LescaEGElena Gallio
Elena GallioURUmberto Ricardi
Umberto Ricardi
+9
Purpose: To investigate whether irradiated volume of pelvic active bone marrow (ACTBM) may predict decreased blood cells nadirs in anal cancer patients undergoing concurrent chemo-radiation. Methods: Forty-four patients were analyzed and pelvic active bone marrow (ACTBM) was characterized employing 18FDG-PET. Dosimetric parameters on dose–volume histograms were correlated to nadirs with generalized linear modeling. Results: ACTBM mean dose was significantly correlated to white blood cell (β = −1.338; 95%CI: −2.455/−0.221; p = 0.020), absolute neutrophil count (β = −1.651; 95%CI: −3.284/−0.183; p = 0.048), and platelets (β = −0.031; 95%CI: −0.057/−0.004; p = 0.024) nadirs. Other dosimetric parameters were found to be correlated (ACTBM-V10,-V20,-V30and-V40). Conclusions: 18FDG-PET is able to define active bone marrow and may predict for decreased blood cells count nadirs.
1 January 2021 in Journal of Surgical Oncology
Journal Article
PNPaola De Nardi
Paola De NardiMassimiliano MistrangeloGBGiovanni Burtulo
Giovanni BurtuloPPPaolo Passoni
Paolo PassoniNSNajla Slim
Najla SlimRRRiccardo Rosati
Riccardo Rosati +8
About Me
Specialized in nuclear medicine, I worked from 2004 to 2006 at HSR in Milan, then at the hospital of Cuneo (2006/2008) and currently in Turin, at the "City of Health and Science". I deal with mono and bifotonic nuclear medicine in the oncology, neurology and lymphology fields.
Pubblications:
-“Role of Positron Emission Tomography-Computed Tomography in the management of Anal Cancer”. Int J Radiat Oncol Biol Phys. 2012 Sept 1;84(1):66-72.
1-8F-FDG uptake and calcificationss on positron emission tomography/ computed tomography in octogenarians with severe aortic stenosys”. Minerva Cardioangiol. 2015 Jun; 63(3):187-92.
-“PET-CT in Anal Cancer: Indications and Limits”, chapter 9. M. Mistrangelo and A. Lesca. Positron Emission Tomography, book edited by Sandro Misciagna, INTECH.
-Dose to specific subregions of pelvic bone marrow defined with FDG-PERT as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients” Med Oncol. 2016 Jul; 33(7):72.
-“Sentinel node biopsy for Anal Carcinoma” Clinics in Oncology 2017, vol 2 Article 1311.
-“Dose to pelvic bone marrow defined with FDG-PET predicts for hematologic nadirs in anal cancer patients treated with concurrent chemoradiation” Cancer Investigation.
-Tailoring the radiotherapy approach in patiens with anal squamous cell carcinoma based on inguinal sentinel lymph node biopsy.- De Nardi et all, J Surg Oncol.2020; 1-7.